Immunic Taps Roche Veteran Lundgren as CEO to Drive MS Drug Commercialization
Event summary
- Erik Lundgren, former Roche/Genentech executive, appointed CEO of Immunic effective June 1, 2026
- Lundgren succeeds Daniel Vitt, who retains scientific strategy role on the board
- Immunic expects pivotal Phase 3 RMS data readout by year-end 2026
- Lundgren granted options for 1 million shares, vesting over 4 years
- Vidofludimus calcium targets both relapsing and progressive MS
The big picture
Immunic's appointment of Lundgren signals its transition from clinical-stage to commercial-ready biotech, capitalizing on his experience with Roche's successful Ocrevus launch. The move comes as Immunic prepares for critical Phase 3 data that could position its oral MS therapy as a differentiated competitor in a market dominated by injectable and infused treatments. Lundgren's commercial expertise will be key as Immunic navigates regulatory approvals and potential market entry.
What we're watching
- Clinical Milestones
- Whether Immunic's Phase 3 ENSURE program delivers positive RMS data by year-end 2026
- Commercial Readiness
- How quickly Lundgren can position Immunic for potential NDA filing and commercialization
- Pipeline Strategy
- The pace at which Immunic advances its PPMS program and other pipeline assets
Related topics